Want to see AU:IBX full AI Analyst Report?
Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Select Model
Select Model
Rating:40Underperform
Price Target:
AU$0.01
â–²(0.00% Upside)
Action:Downgraded
Date:09/26/26
The score is primarily driven by weak financial performance (zero revenue in 2025, persistent losses, negative equity, and ongoing cash burn). Valuation is also constrained because negative earnings make P/E less informative and there is no dividend yield. Technical analysis cannot be reliably assessed due to missing indicators, resulting in a neutral impact.
Positive Factors
MagSense Molecular Imaging Platform
The MagSense platform uses a targeted molecular-imaging approach rather than relying only on conventional anatomical scans. Its intended ability to support earlier cancer detection and disease characterization provides a differentiated long-term development direction, if clinical and commercial execution succeeds.
Negative Factors
No Current Revenue
Revenue falling to zero in 2025 shows that the company has not yet established a dependable commercial revenue base. Without recurring sales, progress depends on successfully converting development work into products and customer adoption, leaving near-term financial self-sufficiency weak.
Read all positive and negative factors
Positive Factors
Negative Factors
MagSense Molecular Imaging Platform
The MagSense platform uses a targeted molecular-imaging approach rather than relying only on conventional anatomical scans. Its intended ability to support earlier cancer detection and disease characterization provides a differentiated long-term development direction, if clinical and commercial execution succeeds.
Read all positive factors
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$6.01M
Dividend YieldN/A
Average Volume (3M)1.31M
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-100.00%
EPS Growth-3.67%
CountryAU
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding801,006,900
10 Day Avg. Volume1,829,881
30 Day Avg. Volume1,314,742
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.21
Price to Sales (P/S)0.00
P/FCF Ratio-1.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Imagion Biosystems Ltd. Business Overview & Revenue Model
Company Description
Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic r...
Imagion Biosystems Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 2.67M | 1.08M | 473.43K | 232.87K |
| Gross Profit | -6.37K | -8.81K | 2.26M | -279.83K | -3.14M | -2.47M |
| EBITDA | -4.67M | -3.58M | -700.09K | -10.30M | -11.03M | -5.62M |
| Net Income | -4.63M | -4.31M | -2.07M | -12.47M | -9.81M | -6.02M |
Balance Sheet | ||||||
| Total Assets | 671.92K | 2.04M | 2.80M | 4.59M | 9.98M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 32.46K | 1.85M | 2.67M | 227.08K | 4.45M | 13.39M |
| Total Debt | 2.19M | 2.56M | 2.85M | 6.04M | 4.60M | 46.02K |
| Total Liabilities | 4.09M | 4.21M | 5.09M | 8.37M | 5.30M | 809.88K |
| Stockholders Equity | -3.42M | -2.16M | -2.28M | -3.79M | 4.68M | 13.31M |
Cash Flow | ||||||
| Free Cash Flow | -4.05M | -4.04M | -1.27M | -8.51M | -9.21M | -5.29M |
| Operating Cash Flow | -4.05M | -4.04M | -1.27M | -8.32M | -8.70M | -5.07M |
| Investing Cash Flow | 0.00 | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K |
| Financing Cash Flow | 3.23M | 3.24M | 3.61M | 4.29M | -962.06K | 5.15M |
Imagion Biosystems Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$820.28M | 37.41 | 3.24% | 4.55% | 25.73% | 390.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$29.86M | -4.03 | -881.94% | ― | 743.51% | -1.52% | |
47 Neutral | AU$18.17M | -1.30 | -35.10% | ― | -9.10% | 31.75% | |
45 Neutral | AU$29.49M | -4.58 | -205.17% | ― | 239.64% | -37.21% | |
40 Underperform | AU$6.01M | -0.66 | 165.88% | ― | -100.00% | -3.67% |
* Healthcare Sector Average
AU:IBX
Imagion Biosystems Ltd.
0.01
-0.02
-69.70%
AU:BDX
BCAL Diagnostics Limited
0.08
0.01
15.71%
AU:RHY
Rhythm Biosciences Ltd.
0.08
>-0.01
-6.90%
AU:GSS
Genetic Signatures Ltd.
0.08
-0.17
-68.00%
AU:IDX
Integral Diagnostics Ltd.
2.20
-0.45
-17.04%
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems Restores MagSense Nanoparticle Manufacturing via nanoComposix Deal
Sep 13, 2026
Imagion Biosystems has signed a Master Service Agreement with nanoComposix, a specialty nanoparticle CDMO, to resume pharmaceutical-grade manufacturing of its MagSense® nanoparticles in alignment with U.S. FDA product quality standards. By ou...
Imagion Biosystems promotes molecular MRI platform for early cancer detection
Sep 3, 2026
Imagion Biosystems has released an investor presentation outlining its molecular MRI platform as a next-generation imaging technology for early cancer detection. The company positions this approach as a breakthrough in oncology imaging, aiming to ...
Imagion Biosystems issues cleansing notice on new options
Sep 1, 2026
Imagion Biosystems has issued a cleansing notice following the allotment of 40,208,334 listed options expiring on 13 December 2027, including options granted to participants in a recent placement and to the lead manager. The options were issued wi...
Imagion Biosystems Seeks ASX Quotation for 7.5 Million New Options
Sep 1, 2026
Imagion Biosystems Limited has applied to the ASX for quotation of new options, designated under the security code IBXO, further integrating these instruments into its listed securities structure. The options relate to securities issued to the lea...
Imagion Biosystems Seeks ASX Quotation for 32.7 Million Options
Sep 1, 2026
Imagion Biosystems has applied to the ASX for quotation of new options under the code IBXO, expanding its listed securities on the market. The company is seeking quotation for a total of 32,708,334 options expiring on 13 December 2027, issued acro...
Imagion Biosystems Options Lapse, Streamlining Capital Structure
Aug 27, 2026
Imagion Biosystems has announced the expiry and cessation of 1,164,597 listed options with the ASX code IBXAAU, which carried an exercise price of $0.90 and an expiry date of August 25, 2026. The options lapsed without being exercised, resulting i...
Imagion Biosystems Details Director’s Milestone-Linked Equity Holdings
Aug 25, 2026
Imagion Biosystems has disclosed a change in Director Robert Romeo Proulx’s interests in the company’s securities, detailing his holdings of ordinary shares, listed and unlisted options, and multiple classes of performance rights tied ...
Imagion Biosystems Half-Year Loss Widens as Auditors Flag Going-Concern Risk
Aug 24, 2026
Imagion Biosystems reported a half-year loss after tax of $1.98 million for the period ended 30 June 2026, a 19.2% increase on the prior corresponding period, with no dividends declared or paid. Net tangible assets per share fell to negative 0.63 ...
Imagion Biosystems Issues New Shares and Options Under Capital Placement
Aug 18, 2026
Imagion Biosystems has issued 152,549,425 fully paid ordinary shares at $0.012 per share and 156,250,023 listed options expiring in December 2027 as part of a previously announced placement. The company lodged a cleansing notice under Section 708A...
Imagion Biosystems Seeks ASX Quotation for Major New Share and Option Issue
Aug 18, 2026
Imagion Biosystems has applied for quotation on the ASX of over 152.5 million new ordinary fully paid shares and an equal volume of options expiring in December 2027. The newly issued securities, tied to a previously announced transaction, expand ...
Imagion Biosystems Issues Tranche 2 Shares and Confirms Regulatory Compliance
Aug 17, 2026
Imagion Biosystems has issued 108,521,193 fully paid ordinary shares as part of Tranche 2 of a previously announced placement, and has lodged a cleansing notice under Section 708A of the Corporations Act. The company confirms it has met its contin...
Imagion Biosystems Seeks ASX Quotation for Over 108 Million New Shares
Aug 17, 2026
Imagion Biosystems Limited has applied for the quotation of 108,521,193 ordinary fully paid shares on the ASX, with the securities issued on August 17, 2026. The application, lodged as a new announcement, confirms the company’s intention to ...
Imagion Biosystems shareholders back capital raising and options at general meeting
Aug 10, 2026
Imagion Biosystems Limited has reported the results of a general meeting at which shareholders voted on a series of capital-related resolutions by poll. The meeting confirmed strong support for the company’s financing activities, with each r...
Imagion Biosystems Plans ASX Share Placement to Raise Capital
Jul 28, 2026
Imagion Biosystems Ltd. has notified the ASX of a proposed issue of up to 17,875,000 ordinary fully paid shares as part of a placement or similar capital-raising structure. The new securities are expected to be issued on 30 November 2026, with the...
Imagion Biosystems Secures Short-Term Non-Dilutive Loan from Executive Chairman
Jul 28, 2026
Imagion Biosystems has secured a non-dilutive short-term funding facility through an unsecured loan agreement with its executive chairman, Robert Proulx, providing up to US$150,000 in working capital. The loan carries an 8% annual interest rate on...
Imagion Biosystems Moves to Fully Virtual General Meeting and Digital Communications
Jul 7, 2026
Imagion Biosystems Limited has called a virtual General Meeting for shareholders to be held on 10 August 2026 at 10:00am AEST via a webinar conferencing facility, with voting eligibility set for registered shareholders as at 8 August 2026. The com...
Imagion Biosystems Extends Siemens Partnership for Pivotal MagSense Trial
Jul 6, 2026
Imagion Biosystems has renewed and extended its collaboration agreement with Siemens Healthineers to support its recently cleared Phase 1b/2 clinical trial of the MagSense HER2 breast cancer imaging agent. Siemens will provide in-kind MRI expertis...
Imagion Biosystems issues new shares and lodges cleansing notice
Jul 2, 2026
Imagion Biosystems has issued 49,346,051 new fully paid ordinary shares at $0.012 per share as part of Tranche 1 of a previously announced placement, and has lodged a cleansing notice under Section 708A of the Corporations Act. The company confirm...
Imagion Biosystems Seeks ASX Quotation for 49 Million New Shares
Jul 1, 2026
Imagion Biosystems has applied for quotation on the ASX of 49,346,051 new fully paid ordinary shares, with an issue date of 30 June 2026. The additional securities, issued under a previously announced transaction, will expand the company’s q...
Imagion Biosystems boosts director’s performance-based equity exposure
Jul 1, 2026
Imagion Biosystems Limited has updated the market on a change in director Robert Romeo Proulx’s interests, reflecting an expansion in his exposure to equity-based incentives. The update details his existing holdings in ordinary shares, liste...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.